PBS Calendars

Page last updated: 1 April 2022

PBS related activities surrounding the PBAC meeting cycles

If you are considering applying to have a drug listed on the PBS, it is recommended that you contact the Office of Health Technology Assessment (OHTA) to discuss the listing steps. If you are unsure of the most appropriate person to contact, the Industry Liaison Officer will be able to assist.

All contact details are available from the PBS contacts page.

PBAC Cycle Timeframe for 2022 - 2023

PBAC Cycle Timeframe for 2022 - 2023 (PDF 206KB) - (Word 32KB)

MEETING

2021/3
3-5 November

2022/1
9-11 March

2022/2
6-8 July

2022/3
2-4 November

2023/1
8-10 March

Activity

Wk

Date

Wk

Date

Wk

Date

Wk

Date

Wk

Date

Deadline for Intent to Apply for integrated co-dependent submissions (Wednesday 5pm AEST)

-8

12 May 2021

-8

8 Sep 2021

-8

12 Jan 2022

-8

11 May 2022

-8

7 Sept 2022

 

-7

 

-7

 

-7

 

-7

 

-7

 

 

-6

 

-6

 

-6

 

-6

 

-6

 

 

-5

 

-5

 

-5

 

-5

 

-5

 

Deadline for Intent to Apply for Category 1-4 and Committee Secretariat submissions; and Standard Re-entry resubmissions (Wednesday 5pm AEST)

 

Deadline for integrated co-dependent submissions (Wednesday 5pm AEST)

-4

9 Jun 2021

 

 

9 Jun 2021

-4

6 Oct 2021

 

 

6 Oct 2021

-4

9 Feb 2022

 

 

9 Feb 2022

-4

8 Jun 2022

 

 

8 Jun 2022

-4

5 Oct 2022




5 Oct 2022

 

-3

 

-3

 

-3

 

-3

 

-3

 

 

-2

 

-2

 

-2

 

-2

 

-2

 

 

-1

 

-1

 

-1

 

-1

 

-1

 

Deadline for Category 1 to 4 and Committee Secretariat submissions; and Facilitated Resolution Pathway and Standard Re-entry Pathway resubmissions (Wednesday 5pm AEST)

0

7 Jul 2021

 

 

 

0

3 Nov 2021

 

 

 

0

9 Mar 2022

0

6 July 2022

0

2 Nov 2022

 

1

 

1

 

1

 

1

 

1

 

 

2

 

2

 

2

 

2

 

2

 

Publication of the main Agenda on web
(Wednesday)

 

Consumer Comments open

(Wednesday)

3

28 Jul 2021

 

28 Jul 2021

3

24 Nov 2021

 

24 Nov 2021

3

30 Mar 2022


30 Mar 2022

3

27 Jul 2022

 

27 Jul 2022

3

23 Nov 2022

 

23 Nov 2022

 

4

 

4

 

4

 

4

 

4

 

 

5

 

5

 

5

 

5

 

5

 

Deadline for Intent to Apply for Early Resolution and Early Re-entry Pathway resubmissions (Friday 5pm AEST)

6

20 Aug 2021

6

17 Dec 2021

6

22 Apr 2022

6

19 Aug 2022

6

16 Dec 2022

Deadline for Early Resolution and Early Re-entry Pathway resubmissions (Friday 5pm AEST)

7

27 Aug 2021

 

7

23 Dec 2021
(24 Dec – 3 Jan Dept shutdown)

7

29 Apr 2022

7

26 Aug 2022

7

22 Dec 2022
(23 Dec – 2 Jan Dept Shutdown)

Publication of the updated Agenda on web

(Friday)

 

 

PBAC December Intracycle ratified minutes (positive outcomes) to Applicants (Friday)

 

8

3 Sept 2021

8

5 Jan 2022
(24 Dec – 3 Jan Dept shutdown)

8

6 May 2022

8

2 Sep 2022

8

4 Jan 2023
(23 Dec – 2 Jan Dept Shutdown)

 

6 Jan 2023

Pre-submission meetings: 8 week cut-off

9

6-10 Sep 2021

9

10-14 Jan 2022

9

9-13 May 2022

9

5-9 Sep 2022

9

9-13 Jan 2023

Submission commentaries to Applicants (Wednesday)

 

PBAC December Intracycle ratified minutes (all other outcomes) to Applicants (Friday)

10

15 Sep 2021

 

10

19 Jan 2022

10

18 May 2022

10

14 Sep 2022

10

18 Jan 2023

 

 

20 January 2023

Applicants’ Pre Subcommittee Responses (PSCRs) to PBAC Secretariat (midday Wednesday)

 

Consumer comments close (Wednesday)

 

PBAC December Intracycle posting of outcomes on website

11

22 Sep 2021

 


22 Sep 2021

11

27 Jan 2022

(PH 26 Jan)


27 Jan 2022

(PH 26 Jan)

11

25 May 2022

 


25 May 2022

11

21 Sep 2022

 

 

21 Sep 2022

11

25 Jan 2023

 

 

25 Jan 2023

 

27 Jan 2023

DUSC meeting (Thursday-Friday)

 

12

30 Sep – 1 Oct 2021

12

3-4 Feb 2022

12

2-3 Jun 2022

12

29-30 Sep 2022

12

2-3 Feb 2023

 

ESC meeting (Monday-Tuesday)

13

5-6 Oct 2021

(PH 4 Oct)

13

7-8 Feb 2022

 

13

6-7 Jun 2022

 

13

4-5 Oct 2022 (PH 3 Oct)

13

6-7 Feb 2023

 

14

 

14

 

14

 

14

 

14

 

Submission overviews, ESC, DUSC & ATAGI (vaccine submissions) advice & summary of consumer comments to Applicants (Wednesday)

15

20 Oct 2021

 

 


 

15

23 Feb 2022

15

22 Jun 2022

15

19 Oct 2022

15

23 Feb 2023

Applicants send Pre-PBAC Responses to PBAC Secretariat (by midday Wednesday)

16

27 Oct 2021

 

16

2 Mar 2022

16

29 Jun 2022

16

26 Oct 2022

16

1 Mar 2023

PBAC meeting Wednesday-Friday
 

17

3-5 Nov 2021

 

17

9-11 Mar 2022

 

17

6-8 July 2022

17

2-4 Nov 2022

17

8-10 Mar 2023

POST PBAC PROCEDURES:

18

 

18

 

18

 

18

 

18

 

 

19

 

19

 

19

 

19

 

19

 

Ratified Minutes (positive outcomes) to Applicants (Friday)

20

26 Nov 2021

20

1 Apr 2022

20

29 Jul 2022

20

25 Nov 2022

20

31 Mar 2023

 

21

 

21

 

21

 

21

 

21

 

PBAC DECEMBER INTRACYCLE (due to Christmas shutdown) (Wednesday)

 

Ratified Minutes (all other outcomes) to Applicants (Friday)

22

 

 

 

10 Dec 2021

22

 

 

 

14 Apr 2022

(PH 15 Apr)

22

 

 

 

12 Aug 2022

22

7 December 2022


9 Dec 2022

22

 

 

 

14 Apr 2023

Post-PBAC meetings with PBAC Chair (Tue-Wed)

 

Posting of outcomes on website following Applicants’ comments (Friday)

23

14-15 Dec 2021

 

17 Dec 2021

 

23

20-21 Apr 2022

(PH 18 April)


22 Apr 2022

23

16-17 Aug 2022

 

19 Aug 2022

23

13-14 Dec 2022

 

 

16 Dec 2022

23

18-19 Apr 2023




21 Apr 2023

Deadline for Independent Review requests for reconsideration at the meeting following the next meeting (Friday)

24

24 Dec 2021

 

24

29 Apr 2022

24

26 Aug 2022

24

23 Dec 2022

24

28 Apr 2023

PBAC INTRACYCLE MEETING

25

10 Dec 2021

25

6 May 2022

25

2 Sep 2022

25

 

25

5 May 2023

 

26

 

26

 

26

 

26

 

26

 

Draft Public Summary Documents (PSDs) to Applicants (Friday)

27

21 Jan 2022

27

20 May 2022

27

16 Sep 2022

27

20 Jan 2023

27

19 May 2023

PBAC Intracycle ratified minutes (positive outcomes) to Applicants (Friday)

28

 

28

27 May 2022

28

23 Sep 2022

28

 

28

26 May 2023

 

29

 

29

 

29

 

29

 

29

 

PBAC Intracycle ratified minutes (all other outcomes) to Applicants (Friday)

30

 

30

10 Jun 2022

30

7 Oct 2022

30

 

30

9 Jun 2023

Finalisation of PSDs (Friday)

 

PBAC Intracycle posting of outcomes on website

31

18 Feb 2022

31

17 Jun 2022

 

17 Jun 2022

31

14 Oct 2022


14 Oct 2022

31

17 Feb 2023

31

16 Jun 2023

 

16 Jun 2023

 

32

 

32

 

32

 

32

 

32

 

PSDs published on website (positive & subsequent rejections) (Friday)

33

4 Mar 2022

33

1 Jul 2022

33

28 Oct 2022

33

3 Mar 2023

33

30 Jun 2023

 

34

 

34

 

34

 

34

 

34

 

PSDs published on website (1st time rejections & deferrals) (Friday)

35

18 Mar 2022

35

15 Jul 2022

35

11 Nov 2022

35

17 Mar 2023

35

14 Jul 2023

PBAC = Pharmaceutical Benefits Advisory Committee

“responsible persons” = legal wording requirement for terminology – previously known as sponsors
DUSC = Drug Utilisation Sub Committee    
ESC = Economic Sub Committee
ATAGI = Australian Technical Advisory Group on Immunisation
PSDs = Public Summary Documents
TBC = To be Confirmed
    
*  These dates may vary based on the number of submissions received    

Accessibility

The documents on this page may not be accessible. If you need help please contact HTA compliance (secretariat.compliance@health.gov.au).

Pre-submission meetings

Sponsors may apply for a pre-submission meeting with the Department at any time. Pre-submission meetings are held throughout the entire PBAC meeting cycle, subject to availability. Please refer to the PBS Calendar above in relation to cut-off dates for applications submitting to the next major submission deadline. Additional information on procedures and links to application and briefing paper templates are outlined in the Procedure guidance for listing medicines on the Pharmaceutical Benefits Scheme.

If the item to be discussed is a co-dependent technology, sponsors should separately contact the Health Technology Assessment (HTA) team (hta@health.gov.au) to discuss the required MSAC processes.

Health technologies are co-dependent if their use needs to be combined (either sequentially or simultaneously) to achieve or enhance the intended clinical effect of either technology.  For example, a drug/test combination where a new medicine seeking listing on the PBS may have a related pathology test that helps to determine the population group for that medicine.

If you have any questions regarding pre-submission meetings, please contact the Pre-submission Meetings Team via email (PBACpresubmissionmeetings@health.gov.au).